Ang Jocelyn, Song Lisa Yun, D'Souza Sara, Hong Irene L, Luhar Rohan, Yung Madeline, Miller Jeffrey H
Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute, and David Geffen School of Medicine, University of California, Los Angeles, California, USA
J Bacteriol. 2016 Sep 22;198(20):2776-83. doi: 10.1128/JB.00391-16. Print 2016 Oct 15.
We tested pairwise combinations of classical base analog mutagens in Escherichia coli to study possible mutagen synergies. We examined the cytidine analogs zebularine (ZEB) and 5-azacytidine (5AZ), the adenine analog 2-aminopurine (2AP), and the uridine/thymidine analog 5-bromodeoxyuridine (5BrdU). We detected a striking synergy with the 2AP plus ZEB combination, resulting in hypermutability, a 35-fold increase in mutation frequency (to 53,000 × 10(-8)) in the rpoB gene over that with either mutagen alone. A weak synergy was also detected with 2AP plus 5AZ and with 5BrdU plus ZEB. The pairing of 2AP and 5BrdU resulted in suppression, lowering the mutation frequency of 5BrdU alone by 6.5-fold. Sequencing the mutations from the 2AP plus ZEB combination showed the predominance of two new hot spots for A·T→G·C transitions that are not well represented in either single mutagen spectrum, and one of which is not found even in the spectrum of a mismatch repair-deficient strain. The strong synergy between 2AP and ZEB could be explained by changes in the dinucleoside triphosphate (dNTP) pools.
Although mutagens have been widely studied, the mutagenic effects of combinations of mutagens have not been fully researched. Here, we show that certain pairwise combinations of base analog mutagens display synergy or suppression. In particular, the combination of 2-aminopurine and zebularine, analogs of adenine and cytidine, respectively, shows a 35-fold increased mutation frequency compared with that of either mutagen alone. Understanding the mechanism of synergy can lead to increased understanding of mutagenic processes. As combinations of base analogs are used in certain chemotherapy regimens, including those involving ZEB and 5AZ, these results indicate that testing the mutagenicity of all drug combinations is prudent.
我们在大肠杆菌中测试了经典碱基类似物诱变剂的两两组合,以研究可能的诱变协同作用。我们检测了胞苷类似物泽布勒林(ZEB)和5-氮杂胞苷(5AZ)、腺嘌呤类似物2-氨基嘌呤(2AP)以及尿苷/胸苷类似物5-溴脱氧尿苷(5BrdU)。我们发现2AP与ZEB的组合具有显著的协同作用,导致超突变性,rpoB基因中的突变频率比单独使用任何一种诱变剂时增加了35倍(达到53,000×10⁻⁸)。2AP与5AZ以及5BrdU与ZEB的组合也检测到了较弱的协同作用。2AP与5BrdU的配对导致抑制作用,使单独使用5BrdU时的突变频率降低了6.5倍。对2AP与ZEB组合产生的突变进行测序显示,A·T→G·C转换出现了两个新的热点,这在单一诱变剂谱中均未得到充分体现,其中一个甚至在错配修复缺陷菌株的谱中也未发现。2AP与ZEB之间的强协同作用可以通过二核苷三磷酸(dNTP)库的变化来解释。
尽管诱变剂已得到广泛研究,但诱变剂组合的诱变效应尚未得到充分研究。在此,我们表明某些碱基类似物诱变剂的两两组合表现出协同或抑制作用。特别是,腺嘌呤和胞嘧啶的类似物2-氨基嘌呤和泽布勒林的组合,与单独使用任何一种诱变剂相比,突变频率增加了35倍。了解协同作用机制有助于增进对诱变过程的理解。由于碱基类似物组合用于某些化疗方案,包括涉及ZEB和5AZ的方案,这些结果表明对所有药物组合进行诱变性测试是谨慎的。